Nobivac Pi, Lyophilisate and Solvent for Suspension for Injection for Dogs

interaction
Safety and efficacy data (viral excretion) are available which demonstrate that
this vaccine can be mixed and administered with the inactivated vaccines in the
Nobivac range against canine leptospirosis caused by all or some of the
following serovars: L. interrogansL.
interrogansL.
interrogansL. kirschneri serogroup
Grippotyphosa serovar Bananal/Liangguang.
The product information of the relevant Nobivac vaccines should be consulted
before administration of the mixed product. When mixed with Nobivac
leptospirosis vaccines at annual revaccination, it has been established that
there is no interference with the anamnestic response induced by the injectable
canine parainfluenza virus component.
After administration with one of the leptospirosis vaccines, a mild and transient
increase in body temperature (≤ 1°C) may occur for a few days after
vaccination, with some pups showing less activity and/or a reduced appetite. A
small transient swelling (≤ 4 cm), which can occasionally be firm and painful on
palpation, may be observed at the site of injection. Any such swelling will either
have disappeared or be clearly diminished by 14 days post-vaccination.
After mixed administration of an overdose of this vaccine and an overdose of
the leptospirosis vaccines in the Nobivac range, transient local reactions such
as diffuse to firm swellings from 1 to 5 cm in diameter may be observed, usually
these will persist no longer than 5 weeks, however some may take a little longer
to completely disappear.
Safety and efficacy data are available which demonstrate that this vaccine can
be mixed and administered with the inactivated vaccine in the Nobivac range
against rabies or the inactivated vaccine against rabies and leptospirosis, where
applicable. After administration with the rabies containing vaccines transient
local reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may
be observed for up to 3 weeks after vaccination. The swellings may be painful
for up to 3 days post dosing.
Safety data are available which demonstrate that this vaccine can be
administered at the same time but not mixed with the inactivated vaccine in the
Nobivac range against Bordetellabronchiseptica
When this vaccine is administered in association with the inactivated vaccine in
the Nobivac range against Bordetellabronchiseptica
antibody response data of this vaccine are the same as when this vaccine is
administered alone.
When this vaccine is used with any of the other Nobivac vaccines referred to
above, the minimum vaccination age for each vaccine must be taken into
account such that at the time of vaccination, the dogs are at or older than the
oldest minimum vaccination age for the individual vaccines.
No information is available on the safety and efficacy of this vaccine when used
with any other veterinary medicinal product except the products mentioned
above. A decision to use this vaccine before or after any other veterinary
medicinal product therefore needs to be made on a case by case basis.